Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

10.14
+0.25002.53%
Post-market: 9.79-0.3542-3.49%19:44 EDT
Volume:2.46M
Turnover:24.76M
Market Cap:1.81B
PE:-6.29
High:10.47
Open:9.73
Low:9.61
Close:9.89
52wk High:11.43
52wk Low:1.78
Shares:178.73M
Float Shares:97.65M
Volume Ratio:1.06
T/O Rate:2.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6113
EPS(LYR):-1.6113
ROE:-41.12%
ROA:-25.35%
PB:3.20
PE(LYR):-6.29

Loading ...

Top Relay Therapeutics Insiders Quietly Cash Out in Coordinated Stock Moves

TIPRANKS
·
Jan 30

Relay Therapeutics : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Jan 26

Relay Therapeutics Raised to Outperform From Perform by Oppenheimer

Dow Jones
·
Jan 26

Oppenheimer Upgrades Relay Therapeutics to Outperform From Market Perform, Price Target is $14

MT Newswires Live
·
Jan 26

Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data

Simply Wall St.
·
Dec 26, 2025

ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn

Reuters
·
Dec 17, 2025

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

THOMSON REUTERS
·
Dec 17, 2025

Will Early Zovegalisib Data in HR+/HER2- Breast Cancer Change Relay Therapeutics' (RLAY) Narrative?

Simply Wall St.
·
Dec 14, 2025

Relay Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
Dec 13, 2025

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Dec 12, 2025

Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer

MT Newswires Live
·
Dec 12, 2025

Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial

Reuters
·
Dec 12, 2025

Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
Nov 24, 2025

Relay Therapeutics (RLAY): A Fresh Board and Narrower Losses—What Does It Mean for Valuation?

Simply Wall St.
·
Nov 17, 2025

Do New Board Appointments Signal a Strategic Shift for Relay Therapeutics (RLAY) as Cash Outlook Improves?

Simply Wall St.
·
Nov 11, 2025

Stock Track | Relay Therapeutics Plummets 7.81% in Pre-market Following Q3 Earnings Miss and Wider Net Loss

Stock Track
·
Nov 07, 2025

Bank of America Securities Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
Nov 07, 2025

Stock Track | Relay Therapeutics Plunges Nearly 6% After Q3 Earnings Miss and Higher Net Loss

Stock Track
·
Nov 07, 2025

Relay Therapeutics slightly misses Q3 net loss estimates, expects cash reserves to fund operations into 2029

Reuters
·
Nov 07, 2025

Relay Therapeutics Expands Board with New Appointments

TIPRANKS
·
Nov 07, 2025